A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models

Nephrology Dialysis Transplantation

Volumn 23, Issue 2, 2008, Pages 497-509

  Izuhara, Yuko ^a   Nangaku, Masaomi ^b   Takizawa, Shunya ^a   Takahashi, Satoru ^c   Shao, Jing ^b   Oishi, Hisashi ^c   Kobayashi, Hiroyuki ^d   Van Ypersele De Strihou, Charles ^e   Miyata, Toshio ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c University of Tsukuba School of Medicine   (Japan)

^d TOKAI UNIVERSITY   (Japan)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Advanced glycation end products; Blood pressure; Oxidative stress; Radical scavenge; Renoprotection

Indexed keywords

1 (5 HYDROXY 3 METHYL 1 PHENYL 1H PYRAZOL 4 YL) 6 METHYL 1,3 DIHYDRO FURO[3,4 C]PYRIDINE 7 OL; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; AMINOPHENAZONE; ASN 9806942; BTB 06198; BTB 06411; BTB 08175; LOSARTAN; NORPHENAZONE; OLMESARTAN; PHENAZONE; PROPYPHENAZONE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDOXAL; PYRIDOXAMINE; TM 2002;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY INJURY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HUMAN CELL; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; FURANS; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY DISEASES; MALE; OXIDATIVE STRESS; PYRIDINES; RATS; RATS, WISTAR;

EID: 44449095037     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm601     Document Type: Article

References (28)

1. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
2. Lewis EJ, Hunsicker LG, Clarke WR et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
3. Brenner BM, Cooper ME, de Zeeuw D et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
4. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in patients with type 2 diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
5. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672-678
6. Miyata T, van Ypersele de Strihou C, Ueda Y et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-2487
7. Nangaku M, Miyata T, Sada T et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212-1222
8. Izuhara Y, Nangaku M, Inagi R et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16: 3631-3641
9. Forbes JM, Cooper ME, Thallas V et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 3274-3282
10. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-1632
11. Nakamura S, Makita Z, Ishikawa S et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997; 46: 895-899
12. Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999; 257: 251-258
13. Figarola JL, Scott S, Loera S et al. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diapetic rats. Diabetologia 2006; 46: 1140-1152
14. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 1989; 264: 21597-21602
15. Miyata T, Taneda S, Kawai R et al. Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 1996; 93: 2353-2358
16. ε-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261: 4889-4894
17. Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW. Age-dependent accumulation of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxymethyl) hydroxylysine in human skin collagen. Biochemistry 1991; 30: 1205-1210
18. Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advanced glycation end-product (AGE) inhibitors. J Biol Chem 2001; 276: 48967-48972
19. Miyata T, Horie K, Ueda Y et al. Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000; 58: 425-435
20. Miyata T, Ishikawa S, Asahi K et al. 2-Isopropylidenehydrazono-4- oxo-thiazolidin-5ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 1999; 445: 202-206
21. Numaguchi K, Egashira K, Takemoto M et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995; 26: 957-962
22. Tsujita K, Shimomura H, Kawano H et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol 2004; 94: 481-484
23. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334
24. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259
25. Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60: 228-234
26. Monnier VM. Transition metals redox: reviving an old plot for diabetic vascular disease. J Clin Invest 2001; 107: 799-801
27. Degenhardt TP, Alderson NL, Arrington DD et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950
28. Metz TO, Alderson NL, Chachich ME, Thrope SR, Baynes JW. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem 2003; 278: 42012-42019